Hepatitis C Virus

Infectious Diseases
9
Pipeline Programs
7
Companies
12
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
3
0
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
5100%
+ 8 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
6 programs
1
2
LDV/SOFPhase 31 trial
SOFPhase 31 trial
SofosbuvirPhase 2Small Molecule1 trial
LDV/SOFN/A
LDV/SOFN/A1 trial
+1 more programs
Active Trials
NCT02951364Completed1,081Est. Jun 2021
NCT02907996Completed2,033Est. Dec 2021
NCT01188772Completed147Est. May 2012
+2 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
ABT-493/ABT-530Phase 31 trial
Active Trials
NCT02636595Completed121Est. Jan 2017
Bristol Myers Squibb
2 programs
1
1
BMS-790052Phase 21 trial
Ortho Tri-Cyclen®Phase 11 trial
Active Trials
NCT01063023Completed20Est. Jun 2010
NCT01170962Completed512Est. Dec 2012
M&
Merck & Co.RAHWAY, NJ
2 programs
1
1
GrazoprevirPhase 2Small Molecule1 trial
boceprevirPhase 1Small Molecule1 trial
Active Trials
NCT01396005Completed21Est. Dec 2011
NCT02105454Completed79Est. May 2015
Pfizer
PfizerNEW YORK, NY
1 program
1
PF-04878691 3mgPhase 11 trial
Active Trials
NCT00810758Completed24Est. Nov 2009
Alliance Pharmaceuticals
1 program
Sofosbuvir/ledipasvirN/ASmall Molecule1 trial
Active Trials
NCT04038320Completed868Est. Jun 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbVieABT-493/ABT-530
Gilead SciencesLDV/SOF
Gilead SciencesSOF
Merck & Co.Grazoprevir
Bristol Myers SquibbBMS-790052
Gilead SciencesSofosbuvir
Merck & Co.boceprevir
Bristol Myers SquibbOrtho Tri-Cyclen®
PfizerPF-04878691 3mg
Alliance PharmaceuticalsSofosbuvir/ledipasvir
Gilead SciencesLDV/SOF
Gilead SciencesSofosbuvir

Clinical Trials (12)

Total enrollment: 5,344 patients across 12 trials

NCT02636595AbbVieABT-493/ABT-530

The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)

Start: Nov 2015Est. completion: Jan 2017121 patients
Phase 3Completed
NCT02073656Gilead SciencesLDV/SOF

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection

Start: Feb 2014Est. completion: Dec 2015335 patients
Phase 3Completed
NCT01838590Gilead SciencesSOF

Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Start: Mar 2013Est. completion: Aug 2014103 patients
Phase 3Completed
NCT02105454Merck & Co.Grazoprevir

Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)

Start: May 2014Est. completion: May 201579 patients
Phase 2Completed
NCT01170962Bristol Myers SquibbBMS-790052

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

Start: Aug 2010Est. completion: Dec 2012512 patients
Phase 2Completed
NCT01188772Gilead SciencesSofosbuvir

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

Start: Aug 2010Est. completion: May 2012147 patients
Phase 2Completed
NCT01396005Merck & Co.boceprevir

A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)

Start: Sep 2011Est. completion: Dec 201121 patients
Phase 1Completed
NCT01063023Bristol Myers SquibbOrtho Tri-Cyclen®

Drug Interaction Oral Contraceptive Pill (OCP)

Start: Jan 2010Est. completion: Jun 201020 patients
Phase 1Completed
NCT00810758PfizerPF-04878691 3mg

Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691

Start: Jan 2009Est. completion: Nov 200924 patients
Phase 1Completed
NCT04038320Alliance PharmaceuticalsSofosbuvir/ledipasvir

Simplified Antiviral Treatment Strategy for Hepatitis C in Ukraine

Start: Mar 2018Est. completion: Jun 2019868 patients
N/ACompleted
NCT02951364Gilead SciencesLDV/SOF

Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea

Start: Dec 2016Est. completion: Jun 20211,081 patients
N/ACompleted
NCT02907996Gilead SciencesSofosbuvir

Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea

Start: Sep 2016Est. completion: Dec 20212,033 patients
N/ACompleted

Related Jobs in Infectious Diseases

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
8h ago
$179K - $237K/yr

Executive Director, Global Medical Expert HIV Prevention - GMA Virology & Inflammation

Gilead Sciences
United States - Field
20h ago
$317K - $411K/yr

Sr. Engineer, Process Systems (Contract)

VaxCyte
Visp, Valais, Switzerland
23h ago

Contract Senior Research Associate, Protein Science

Keros Therapeutics
Lexington, Massachusetts, United States
23h ago

Director, Health Economics & Outcomes Research (HEOR)

VaxCyte
San Carlos, California, United States
Yesterday
$242K - $282K/yr

Senior Manager, Contract Account Performance Specialist, Contract Strategy

Pfizer
Remote
Yesterday
$124K - $207K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
7 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)